Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Sotgiu, E. Pietersen, R. Centis, M. Davids, A. Piana, D. Vaghela, K. Kliiman, L. D‘Ambrosio, G. Theron, G.B. Migliori, K. Dheda (Sassari, Tradate, Italy; Cape Town, South Africa; Tartu, Estonia). Poor treatment outcomes of XDR-TB patients in resource-limited settings. Eur Respir J 2012; 40: Suppl. 56, 3316

Member's Comments

No comment yet.

Related content which might interest you: A review of the management of MDR-TB in a resource-limited setting in India Source: Annual Congress 2010 - Global tuberculosis control Year: 2010 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 MDR-TB treatment in prison setting Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Managing adult and children XDR-TB cases with limited clinical options Source: International Congress 2018 – CC4 Tuberculosis Year: 2018 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Management of severe COVID-19 in resource-poor settings Source: Virtual Congress 2020 – Hot topics in intensive care: COVID-19: Lessons learned Year: 2020 Clinical management improves the treatment outcome of MDR-TB patients Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Outcomes of MDR-TB treatment in penitentiary medical setting Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008 Treatment outcomes of MDR-TB and HIV co-infection in Europe Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016 Year: 2017 Time to sputum culture conversion as a prognostic marker for end-of-treatment outcome in the first cohorts of MDR-TB patients managed in a Nigerian tertiary hospital Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Pulmonary rehabilitation in low-resource settings Source: Eur Respir Monogr 2021; 93: 273-293 Year: 2021 The reasons of unfavorable outcomes of treatment in pulmonary tuberculosis patients in Kyrgyzstan Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004